Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trends in Surgical Management of Hidradenitis Suppurativa.
Wendland Z, Jiang Z, Sayed CJ, Goldfarb N. Wendland Z, et al. Among authors: sayed cj. Dermatol Surg. 2024 Nov 27. doi: 10.1097/DSS.0000000000004496. Online ahead of print. Dermatol Surg. 2024. PMID: 39601422 No abstract available.
Bimekizumab for the treatment of hidradenitis suppurativa.
Shams RB, Sayed CJ. Shams RB, et al. Among authors: sayed cj. Immunotherapy. 2024;16(16-17):1005-1013. doi: 10.1080/1750743X.2024.2401308. Epub 2024 Sep 19. Immunotherapy. 2024. PMID: 39297706 Review.
Inpatient Management of Hidradenitis Suppurativa: A Delphi Consensus Study.
Needham M, Pichardo R, Alavi A, Chang AY, Daveluy S, DeNiro KL, Dewan A, Eshaq M, Fox L, Hsiao JL, Kaffenberger BH, Kirby JS, Kroshinsky D, Ortega-Loayza AG, Manusco JB, Micheletti RG, Mostaghimi A, Nelson CA, Pasieka HB, Porter ML, Resnik BI, Sayed CJ, Shi VY, Shields BE, Strowd LC. Needham M, et al. Among authors: sayed cj. Cutis. 2024 Jun;113(6):251-254. doi: 10.12788/cutis.1027. Cutis. 2024. PMID: 39082985
Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens.
Sampath AJ, Westerkam LL, Blum FR, Alhusayen R, Bechara FG, Caffrey J, Carmona-Rivera C, Chandran NS, George R, Goldberg SR, Gudjonsson JE, Hansen SL, Ingram JR, Kirby B, Marzano AV, Matusiak Ł, Orgill DP, Prens E, van der Zee HH, van Straalen KR, Zouboulis CC, Byrd AS, Frew JW, Lowes MA, Naik HB, Sokumbi O, Mi QS, Miedema JR, Googe PB, Sayed CJ. Sampath AJ, et al. Among authors: sayed cj. J Invest Dermatol. 2024 Jun 18:S0022-202X(24)00443-3. doi: 10.1016/j.jid.2024.02.041. Online ahead of print. J Invest Dermatol. 2024. PMID: 38901775
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC. Kimball AB, et al. Among authors: sayed cj. Lancet. 2024 Jun 8;403(10443):2504-2519. doi: 10.1016/S0140-6736(24)00101-6. Epub 2024 May 22. Lancet. 2024. PMID: 38795716 Clinical Trial.
55 results